So, PME have moved in to mammography. But no fanfare or bunting. There should be. This is a significant broadening of the offering.
Consider that this new stream will be available to existing customers. Those customers have contracted minimums based purely on radiology. it will be very easy for existing customers to exceed their contracted minimums under this scenario.
Visage accelerates the pace of enterprise imaging innovation
SAN DIEGO, Feb. 22, 2018 /PRNewswire/ -- Visage Imaging, Inc. ("Visage"), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced the latest version of the Visage® 7 Enterprise Imaging Platform, Visage 7.1.11, has been released for global availability. Visage 7 enables enterprise imaging with amazingly fast, thin-client, server-side processing technology, as well as simple diagnostic mobile access via Visage Ease Pro®.
- Visage has a proven track record of rapidly translating customer needs into delivered software. Visage 7.1.11 includes more than 170 software enhancements, most of which have been customer-driven, reflecting the contributions of the world's most sophisticated imaging organizations.
- Visage 7.1.11 includes full support for DICOM standard Breast Projection Objects (e.g., Breast Projection X-Ray Image Storage DICOM SOP Class). This is significant because the vendor responsible for one of the most widely adopted digital breast tomosynthesis (DBT) systems announced a recent change from proprietary to DICOM standard Breast Projection Objects. With this change, Visage 7's industry-leading support for multi-modality breast imaging has gotten even stronger, further bolstering Visage's One Viewer® philosophy.
- Forums
- ASX - By Stock
- Mamography
So, PME have moved in to mammography. But no fanfare or bunting....
-
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PME (ASX) to my watchlist
(20min delay)
|
|||||
Last
$227.64 |
Change
5.890(2.66%) |
Mkt cap ! $17.90B |
Open | High | Low | Value | Volume |
$225.00 | $229.57 | $223.37 | $80.03M | 351.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4 | $227.60 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$227.72 | 3210 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1231 | 14.800 |
1 | 1231 | 14.760 |
1 | 293 | 14.750 |
1 | 510 | 14.730 |
1 | 941 | 14.720 |
Price($) | Vol. | No. |
---|---|---|
14.830 | 466 | 1 |
14.840 | 1685 | 1 |
14.860 | 771 | 1 |
14.870 | 677 | 1 |
14.880 | 941 | 2 |
Last trade - 16.10pm 25/11/2024 (20 minute delay) ? |
Featured News
PME (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online